Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Pfizer Inc (IRSH)

  Print      Mail a friend

Tuesday 14 November, 2017

Pfizer Inc

Press Release

RNS Number : 5000W
Pfizer Inc
14 November 2017



                                           Media Contact:

November 14, 2017                          Dean Mastrojohn

(212) 733-6944


Investors Contact:

Chuck Triano

(212) 733-3901


It should be noted that the below was released in the U.S on November 13, 2017


Pfizer Names Albert Bourla Chief Operating Officer

- - -

John Young named Group President, Pfizer Innovative Health

Angela Hwang named Group President, Pfizer Essential Health



NEW YORK, N.Y., November 13 - Pfizer Inc. (NYSE: PFE) today announced that Albert Bourla has been named Chief Operating Officer effective January 1, 2018.     


"The naming of a Chief Operating Officer comes at a time when our business is strong as we continue to advance our strategy while also managing a dynamic and challenging external environment, said Ian Read, Pfizer Chairman and CEO. 


"The addition of a COO will enable me to spend more time focusing on the company's long term strategic direction, ensuring continued R&D productivity and engaging with government policy and industry leaders on key issues facing the future of the healthcare industry." 


Albert Bourla, 56, has been the Group President of Pfizer's Innovative Health Business since the beginning of 2016.  Under his leadership revenues for the Pfizer Innovative Health business grew 11% operationally in 2016 and in the first nine months of 2017 have grown 9% operationally.  Prior to his current position Dr. Bourla was the Group President for Pfizer's Vaccines, Oncology and Consumer Healthcare businesses where he was instrumental in building a strong and competitive position in Oncology and expanded the company's leadership in vaccines. 


Over the course of his career Dr. Bourla has held a number of senior global positions across a range of businesses and geographies.    


Read continued, "Albert is a proven and trusted leader with over two decades of leadership experience and a demonstrated track record for delivering strong business results.  He possesses the right combination of skills, knowledge, strengths and a deep commitment to Pfizer's culture that make him the clear choice to become Pfizer's COO."   


As General Manager of the company's Established Products Business Unit he advanced the company's efforts to build a strong post-patent business by spear-heading efforts that maximized the lifecycle of key brands following loss of exclusivity.


Prior to leading the Established Products business, Dr. Bourla was the Area President for Pfizer's Animal Health business across Europe, Africa, and Asia Pacific where he successfully managed the integration of Wyeth's Animal Health Business (Fort Dodge) with Pfizer in these global markets.   


Dr. Bourla has significant scientific expertise.  He is a Doctor of Veterinary Medicine and holds a PhD degree in the Biotechnology of Reproduction from the Veterinary School of Aristotle University.


Effective January 1, 2018 John Young, Group President, Pfizer Essential Health becomes Group President, Pfizer Innovative Health.  Angela Hwang, Global President and General Manager for Pfizer Inflammation & Immunology will succeed John Young as Group President, Pfizer Essential Health. 


Mr. Young has held a number of senior leadership positions across Pfizer including as President of the Primary Care Business.  He is a scientist by training and has deep knowledge of the company's innovative biopharmaceutical portfolio having led the commercial and clinical development of medicines in key therapeutic areas including cardiovascular disease, diabetes and pain. 


Mr. Young received a BSc in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School.  He will report to Dr. Bourla and will continue to be a member of the company's Executive Leadership Team.


Ms. Hwang joined the company in 1997 in the company's Corporate Strategic Planning and Policy Group.  Her experience includes leadership roles within the Innovative Health and Essential health businesses as Global President Pfizer Inflammation and Immunology, Regional head for U.S. Vaccines, Vice President of Emerging Markets for the Primary Care business and Vice President of the U.S. Brands business within Essential Health.  In her current role she has been responsible for the growth of products such as Xeljanz and Eucrisa and building a strong pipeline around rheumatology, gastroenterology and dermatology.


Ms. Hwang received her Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town and a Masters of Business Administration from Cornell University.  She will become a member of the company's Executive Leadership team and will report to Dr. Bourla.


Additional members of the Pfizer Executive Leadership team reporting to Dr. Bourla will be:    

Kirsten Lund-Jurgensen - Executive Vice President and President Pfizer Global Supply

Rod MacKenzie - Executive Vice President, Chief Development Officer

Laurie Olson - Executive Vice President, Strategy and Commercial Operations


In addition to Dr. Bourla, the following members of Pfizer's Executive Leadership team will continue to report to Ian Read:


Frank D'Amelio - Executive Vice President, Business Operations and Chief Financial Officer

Mikael Dolsten - Executive Vice President and President, Worldwide Research & Development 

Chuck Hill - Executive Vice President, Worldwide Human Resources

Rady Johnson - Executive Vice President, Chief Compliance and Risk Officer

Doug Lankler - Executive Vice President, General Counsel

Freda Lewis-Hall - Executive Vice President and Chief Medical Officer

Sally Susman - Executive Vice President, Corporate Affairs




# # # # #




This announcement has been issued through the Companies Announcement Service of

The Irish Stock Exchange


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t